Lilly lands clinical-phase pain drug via deal with Asahi Kasei

Lilly lands clinical-phase pain drug via deal with Asahi Kasei

Source: 
Fierce Biotech
snippet: 

Eli Lilly has struck a deal to buy the near-global rights to a P2X7 receptor antagonist from Asahi Kasei Pharma. The agreement will give Lilly control of a treatment for neuroinflammatory pain conditions that recently completed phase 1 studies.